Skip to content

DE · SHL.DE · MEDICAL - DEVICES

Siemens Healthineers AG (SHL.DE) intrinsic value and stock valuation

$42.96as of 2026-11-21 · Mkt cap 38.83B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Siemens Healthineers AG DCF and intrinsic value

InvestorsCraft values SHL.DE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SHL.DE’s statements →

Siemens Healthineers AG Graham Number

Graham Number: $26.38d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Forchheim 91052 siemens-healthineers.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$23.4B+10.1% 5y CAGRd
20152025
Net income
$2.14B+8.7% 5y CAGRd
20152025
Free cash flow
$2.27B+12.7% 5y CAGRd
20152025
Total equity
$18.1B+7.7% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$23.4B$22.4B$21.7B$21.7B$18B
Operating income$3.44B$3.3B$2.44B$3.06B$2.78B
Net income$2.14B$1.94B$1.51B$2.04B$1.73B
EPSd$1.91M$1.73M$1.34M$1.81M$1.56M
Operating cash flow$3.08B$2.47B$1.81B$2.26B$2.78B
Capital expenditure-$-818M-$-696M-$-838M-$-852M-$-674M
Free cash flow$2.27B$1.77B$971M$1.4B$2.11B
Total assets$44.4B$46.1B$46.7B$49.1B$41.9B
Total debt$15.1B$16.2B$16.7B$16.7B$14.3B
Net debt$12.9B$13.5B$15B$15.2B$13B
Total equity$18.1B$18.2B$18.1B$19.9B$16.1B
Cash and short-term investments$2.18B$2.68B$1.64B$1.44B$1.32B
Income statement
20252024202320222021
Revenue$23.4B$22.4B$21.7B$21.7B$18B
Cost of revenue$14.3B$13.9B$14B$13.6B$11B
Gross profit$9.03B$8.47B$7.71B$8.14B$6.95B
Research and development expenses$1.96B$1.92B$1.87B$1.79B$1.55B
Selling, general and administrative expenses$3.64B$3.25B$3.4B$3.29B$2.63B
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$5.6B$5.17B$5.27B$5.07B$4.18B
Cost and expenses$19.9B$19.1B$19.2B$18.7B$15.2B
Interest income$99M$119M$85M$48M$33M
Interest expense$425M$476M$296M$118M$83M
Depreciation and amortization$1.3B$1.22B$1.56B$1.34B$1.04B
Ebitda$4.58B$4.22B$3.78B$4.26B$3.52B
Operating income$3.44B$3.3B$2.44B$3.06B$2.78B
Total other income/expenses, net-$-582M-$-777M-$-512M-$-264M-$-373M
Income before tax$2.85B$2.52B$1.93B$2.8B$2.4B
Income tax expense$685M$564M$403M$746M$658M
Net income$2.14B$1.94B$1.51B$2.04B$1.73B
Weighted average shares outstanding$1.12B$1.12B$1.12B$1.12B$1.1B
Weighted average diluted shares outstanding$1.12B$1.12B$1.12B$1.13B$1.1B
Balance sheet
20252024202320222021
Cash and short-term investments$2.18B$2.68B$1.64B$1.44B$1.32B
Net receivables$7.27B$7.21B$7.48B$7.06B$6.01B
Inventory$4.14B$4.18B$4.29B$4.01B$3.18B
Total current assets$14.1B$14.4B$14.1B$13.4B$10.8B
Property, plant and equipment, net$4.71B$4.48B$4.21B$4.27B$3.71B
Goodwill and intangible assets$23.6B$24.7B$25.8B$27.8B$25.5B
Long-term investments$976M$1.41B$1.6B$2.61B$962M
Total non-current assets$30.3B$31.6B$32.5B$35.7B$31.1B
Total assets$44.4B$46.1B$46.7B$49.1B$41.9B
Accounts payable$2.3B$2.13B$2.2B$2.32B$1.92B
Short-term debt$3.72B$2.75B$4.4B$2.84B$2.15B
Deferred revenue$3.64B$3.63B$3.63B$3.75B$2.9B
Total current liabilities$12.6B$11.6B$13.4B$12B$10.1B
Long-term debt$11.3B$13.5B$12.3B$13.8B$12.2B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$13.6B$16.2B$15.1B$17.2B$15.8B
Capital lease obligations$505M$533M$449M$468M$481M
Total liabilities$26.3B$27.8B$28.6B$29.2B$25.9B
Common stock$1.13B$1.13B$1.13B$1.13B$1.13B
Retained earnings$3.24B$2.15B$1.38B$894M-$-300M
Accumulated other comprehensive income (loss)-$-1.68B-$-522M$340M$2.36B-$-369M
Total equity$18.1B$18.2B$18.1B$19.9B$16.1B
Total investments$976M$1.41B$1.6B$2.61B$962M
Total debt$15.1B$16.2B$16.7B$16.7B$14.3B
Net debt$12.9B$13.5B$15B$15.2B$13B
Cash flow statement
20252024202320222021
Net income$2.14B$1.94B$1.51B$2.04B$1.73B
Depreciation and amortization$1.3B$1.22B$1.56B$1.34B$1.04B
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-581M-$-605M-$-842M-$-1.13B$53M
Accounts receivable-$-410M-$-422M-$-773M-$-489M-$-718M
Inventory-$-76M$39M-$-453M-$-481M-$-22M
Accounts payable$229M-$-62M-$-20M$247M$318M
Net cash provided by operating activities$3.08B$2.47B$1.81B$2.26B$2.78B
Investments in property, plant and equipment-$-818M-$-696M-$-838M-$-852M-$-674M
Acquisitions, net-$-86M$34M-$-224M-$-14M-$-13.45B
Net cash used for investing activities-$-906M-$-666M-$-1.07B-$-868M-$-14.14B
Common stock issued$0.00$0.00$18M$1M$2.31B
Common stock repurchased-$-301M-$-10M-$-421M-$-309M-$-255M
Dividends paid-$-1.07B-$-1.06B-$-1.07B-$-955M-$-856M
Net cash used for financing activities-$-2.59B-$-1.3B-$-380M-$-1.4B$12B
Net change in cash-$-508M$1.04B$206M$114M$666M
Cash at end of period$2.18B$2.68B$1.64B$1.44B$1.32B
Operating cash flow$3.08B$2.47B$1.81B$2.26B$2.78B
Capital expenditure-$-818M-$-696M-$-838M-$-852M-$-674M
Free cash flow$2.27B$1.77B$971M$1.4B$2.11B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Siemens Healthineers AG

        Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.

        CEO
        Bernhard Montag
        Employees
        72K
        Beta
        0.80

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Siemens Healthineers AG (SHL.DE)?

        InvestorsCraft does not currently publish an intrinsic value for SHL.DE. How the IC value is calculated.

        Is SHL.DE undervalued?

        InvestorsCraft does not publish an undervaluation signal for SHL.DE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.